Health
Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF – TCTMD
Prospective studies are needed and mechanisms unclear, but the findings raise hopes for off-target benefits, says J. Emanuel Finet.
Compared with valsartan alone, the angiotensin receptor-neprilysin inhibitor (ARNI) / (Entresto; Novartis) reduces triglycerides among patients with heart failure and preserved ejection fraction (HFpEF), according to results from a PARAGON-HF subanalysis. The effect was particularly marked in patients with higher triglycerides at baseline.
Our research adds to the growing literature of the favorable metabolic effects of sacubitril/valsartan, Senthil Selvaraj, MD (Hospital of the University of Pennsylvania,…
-
Business23 hours agoIs Warren Buffett’s Berkshire Hathaway the smartest investment you can make today?
-
General23 hours agoTop chess player Magnus Carlsen forced into draw in historic game against over 134,000 people
-
Noosa News9 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
General23 hours agoTaiwan’s President Lai Ching-te calls for peace and dialogue with China while also calling for defence boosts